The Pharmaceutical Journal
Vol 271 No 7261 p169
9 August 2003

This article
Reprint
Photocopy

News summary

Related websites
Journal of the National Cancer Institute abstract (more)

Paclitaxel useful in lung cancer

A triple therapy regimen of paclitaxel (Taxol), etoposide and carboplatin appears to improve survival in patients with small-cell lung cancer when compared with a regimen of etoposide, carboplatin and vincristine. Tumour response rates for the two regimens were similar. However, the three-year survival rate for patients in the paclitaxel group was 17 per cent compared with 9 per cent for patients in the vincristine group (Journal of the National Cancer Institute 2003;95:1118).